Comparison 30. Hylan G‐F 20 versus hyaluronan (Also see Artzal, BioHy (Arthrease), Hyalgan and Orthovisc versus Hylan G‐F 20).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain on weight bearing (0‐100 mm VAS)	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 1 to 4 weeks post‐injection	3	326	Mean Difference (IV, Fixed, 95% CI)	‐2.06 [‐7.45, 3.32]
1.2 5 to 13 weeks post‐injection	3	322	Mean Difference (IV, Fixed, 95% CI)	‐6.59 [‐12.46, ‐0.73]
1.3 14 to 26 weeks post‐injection	1	176	Mean Difference (IV, Fixed, 95% CI)	‐5.0 [‐14.98, 4.98]
2 Pain at night (0‐100 mm VAS)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 1 to 4 weeks post‐injection	2	150	Mean Difference (IV, Fixed, 95% CI)	‐7.07 [‐13.41, ‐0.73]
2.2 5 to 13 weeks post‐injection	2	146	Mean Difference (IV, Fixed, 95% CI)	‐3.50 [‐11.34, 4.34]
2.3 14 to 26 weeks post‐injection	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Function: improvement in knee movement (0‐100 mm VAS)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 1 to 4 weeks post‐injection	2	150	Mean Difference (IV, Fixed, 95% CI)	‐0.50 [‐10.30, 9.30]
3.2 5 to 13 weeks post‐injection	2	146	Mean Difference (IV, Fixed, 95% CI)	12.50 [2.70, 22.30]
4 Patient global evaluation of treatment efficacy (improvement: 0‐100 mm VAS)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 1 to 4 weeks post‐injection	2	150	Mean Difference (IV, Fixed, 95% CI)	2.00 [‐7.80, 11.80]
4.2 5 to 13 weeks post‐injection	2	146	Mean Difference (IV, Fixed, 95% CI)	9.50 [‐0.30, 19.30]
5 Safety: total withdrawals overall	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 5 to 13 weeks post‐injection	2	146	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.17, 5.55]
6 Safety: number of patients with local reactions	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 5 to 13 weeks post‐injection	2	146	Risk Ratio (M‐H, Fixed, 95% CI)	2.91 [0.47, 17.86]